HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

Nature Medicine

Volumn 8, Issue 3, 2002, Pages 225-232

  Sgadari, Cecilia ^a   Barillari, Giovanni ^a,b   Toschi, Elena ^a   Carlei, Davide ^a   Bacigalupo, Ilaria ^a   Baccarini, Sara ^a   Palladino, Clelia ^a   Leone, Patrizia ^a   Bugarini, Roberto ^a   Malavasi, Laura ^a   Cafaro, Aurelio ^a   Falchi, Mario ^a   Valdembri, Donatella ^c   Rezza, Giovanni ^a   Bussolino, Federico ^c   Monini, Paolo ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; INDINAVIR; PACLITAXEL; PROTEINASE INHIBITOR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; INFLAMMATORY CELL; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEROCONVERSION; STEM CELL; TUMOR REGRESSION; VIRUS REPLICATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EXTRAEMBRYONIC MEMBRANES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LYMPHOKINES; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; SAQUINAVIR; SARCOMA, KAPOSI; SKIN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 0036131462     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0302-225     Document Type: Article

References (50)

1. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation
2. Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorigenesis
3. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
4. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma
5. +T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: An immune response to human herpesvirus-8 infection?
6. Monoclonal origin of multicentric Kaposi's sarcoma lesions
7. Kaposi's sarcoma: A result of the interplay among inflammatory cytokines, angiogenic factors and viral agents
8. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma
9. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma
10. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development
11. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial-cell growth factor in T cells: Implications for acquired immunodeficiency syndrome-associated vasculopathy
12. Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability
13. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice
14. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the αvβintegrin
15. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS
16. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
17. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells
18. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the α5β1 and αvβ3 integrins and by mobilizing sequestered basic fibroblast growth factor
19. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 tat protein and basic fibroblast growth factor
20. Angiogenesis in cancer and other diseases
21. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
22. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
23. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome
24. HIV-1 protease inhibitors. A review for clinicians
25. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
26. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
27. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
28. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells
29. Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function
30. Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects
31. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals
32. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
33. Tumor targeting with a selective gelatinase inhibitor
34. Mechanism of paclitaxel activity in Kaposi's sarcoma
35. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis
36. The microtubule-affecting drug paclitaxel has antiangiogenic activity
37. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
38. Development of matrix metalloproteinase inhibitors in cancer therapy
39. Permanent cell line expressing human factor VIII-related antigen established by hybridization
40. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk1/KDR receptor on vascular endothelial cells
41. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
42. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
43. Identification of human herpesvirus 8-specific cytotoxic T-cell responses
44. + cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals
45. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy
46. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma
47. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin
48. + cell counts greater than 400 per cubic millimeter
49. Spontaneous regression of Kaposi's sarcoma in patients with AIDS
50. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy